Celldex Therapeutics, Inc. (CLDX): Total Assets
$582.98M
As of 2025-12-31
$782.35M
As of 2026-06-30
+18.2%
3-year compound annual growth
+19.8%
5-year compound annual growth
+5.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $582.98M | -26.4% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $792.34M | +70.2% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $465.63M | +32.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $352.74M | -20.7% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $444.65M | +88.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $235.84M | +91.8% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $122.93M | -21.1% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $155.81M | -50.6% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $315.62M | -17.7% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $383.36M | +13.6% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $337.58M | +36.1% | 2017-03-14, Balance as of period end |
| 2014-12-31 | $248.01M | -28.5% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $347.10M | +176.5% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $125.54M | +28.1% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $97.99M | -10.9% | 2013-03-08, Balance as of period end |
| 2010-12-31 | $109.94M | n/a | 2012-03-08, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $582.98M | -26.4% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $6.90M | -26.6% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $25.76M | -26.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $6.76M | +13.7% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.24M | +59.8% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $5.46M | -0.6% |
| Immucell Corp (ICCC) | 2025-12-31 | $42.53M | -5.7% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $103.58M | -12.8% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $842.13M | -29.3% |
Compare CLDX, VNRX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗